Telmisartan and Amlodipine Versus Monocomponent Tablets
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will be an open-label, randomized, two-treatment, two-period, two-sequence
crossover study to evaluate the bioequivalence of the amlodipine component of Boehringer
Ingelheim Pharma GmbH & Co. KGs 80 mg telmisartan/10 mg amlodipine fixed dose combination
tablet to the corresponding mono-component amlodipine tablets, 10 mg (Pfizers Norvasc).